Nuvectis Pharma annual operating income
2021
2022
2023
2024
2025
Nuvectis Pharma Operating Income Growth & History (NVCT)
Nuvectis Pharma's operating income was −$27.6M for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$27.6M | −$7.7M | — |
| 2024 | 2024-12-31 | −$19.8M | $3.0M | — |
| 2023 | 2023-12-31 | −$22.9M | −$3.7M | — |
| 2022 | 2022-12-31 | −$19.2M | −$6.3M | — |
| 2021 | 2021-12-31 | −$12.9M | — | — |
Nuvectis Pharma quarterly operating income
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.2M | −$602,000 | — |
| Q1 2026 | 2026-03-31 | −$6.3M | −$692,000 | — |
| Q4 2025 | 2025-12-31 | −$7.6M | −$1.2M | — |
| Q3 2025 | 2025-09-30 | −$7.8M | −$3.4M | — |
| Q2 2025 | 2025-06-30 | −$6.6M | −$2.0M | — |
| Q1 2025 | 2025-03-31 | −$5.6M | −$1.2M | — |
| Q4 2024 | 2024-12-31 | −$6.4M | $417,000 | — |
| Q3 2024 | 2024-09-30 | −$4.4M | $1.8M | — |
| Q2 2024 | 2024-06-30 | −$4.6M | $1.1M | — |
| Q1 2024 | 2024-03-31 | −$4.4M | −$295,000 | — |
| Q4 2023 | 2023-12-31 | −$6.9M | −$88,000 | — |
| Q3 2023 | 2023-09-30 | −$6.2M | −$220,000 | — |
| Q2 2023 | 2023-06-30 | −$5.8M | −$2.2M | — |
| Q1 2023 | 2023-03-31 | −$4.1M | −$1.2M | — |
| Q4 2022 | 2022-12-31 | −$6.8M | −$4.5M | — |
| Q3 2022 | 2022-09-30 | −$5.9M | −$1.3M | — |
| Q2 2022 | 2022-06-30 | −$3.6M | $2.4M | — |
| Q1 2022 | 2022-03-31 | −$2.9M | −$2.9M | — |
| Q4 2021 | 2021-12-31 | −$2.3M | — | — |
| Q3 2021 | 2021-09-30 | −$4.7M | — | — |
| Q2 2021 | 2021-06-30 | −$5.9M | — | — |
| Q1 2021 | 2021-03-31 | −$23,000 | — | — |
Nuvectis Pharma operating income trends
Between the periods ended 2021-12-31 and 2025-12-31, Nuvectis Pharma's operating income decreased from −$12.9M to −$27.6M, a change of −$14.7M. The latest reported quarter, Q2 2026, shows −$7.2M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗Community posts
Nuvectis’ partner reports expanded glioma responses for experimental BRAF inhibitor
Nuvectis ($NVCT) reported expanded Phase 1b results for NXP200 from partner Haisco’s Chinese study in recurrent or progressive BRAF V600-mutated glioma. Tumor responses occurred in eight of twenty evaluable patients with high-grade disease ...
